Permanent Girth Injections: The Clinical Truth About PMMA in 2026
Introduction: Why “Permanent” Is the Most Misused Word in Penile Enhancement Marketing
Men who search for “permanent girth injections” are rarely beginners. Most have already researched temporary hyaluronic acid (HA) fillers, compared providers, and weighed the cost of repeat touch-ups. What they want to know is simple: is a permanent option worth an irreversible commitment?
That question deserves a straight answer, and it rarely gets one. Many provider websites use “permanent” as a marketing hook. They cite the single most favorable PMMA satisfaction study and leave out the material’s FDA status and its long-term complication data.
This article takes a different approach. It offers a clinically honest, side-by-side breakdown of what “permanent” actually means biologically for each filler and implant category, including the data competitors tend not to show. It is written for safety-conscious professionals who make high-stakes decisions on evidence rather than hype.
For context, Stoller Medical Group does not offer off-label permanent implant materials. That is a deliberate clinical choice, not a limitation, and the reasoning is laid out below.
What “Permanent” Actually Means: The Biology Behind Each Filler Category
Most competitor content skips this point entirely: “permanent” is not one mechanism. It describes four biologically distinct outcomes. Encapsulation, an inert device, a living graft, and scaffold-and-resorb behavior all behave differently in the body, and those differences shape every risk discussed in this article.
PMMA Microsphere Encapsulation
Polymethylmethacrylate (PMMA) is a non-absorbable soft tissue filler, historically chosen specifically for its permanence. After injection, the PMMA microspheres become encapsulated in granulation tissue, and collagen and vascular tissue then form around each sphere.
The “permanence,” in other words, is the body’s scar-tissue response to a foreign material. It is not seamless integration. The same encapsulation process is also the root cause of later nodules and irregularities, because the body is permanently walling off something it recognizes as foreign.
Inert Silicone Implants (Device-Based, Not Injectable)
A solid silicone device such as Penuma is surgically placed, not injected, and it does not depend on a collagen response to stay in place. As of May 2022, Penuma is the only FDA-cleared device for cosmetic penile enhancement. It is designed to increase flaccid and erect girth and flaccid length, but not erect length.
That clearance applies to a device, not a filler. Even this legitimate pathway carries real risk, covered later in this article.
Autologous Fat Grafts
Fat grafting harvests a man’s own fat cells and reinjects them, in theory creating a “natural permanent” result if the transplanted cells survive. In practice, survival is inconsistent. Instead of integrating stably, the tissue can develop nodular hyperplasia, atrophy, or contracture. The American Urological Association (AUA) states explicitly that fat injection into the penis is not safe or reproducibly effective.
Collagen-Stimulating Semi-Permanent Fillers (HA/PLA)
Hyaluronic acid and polylactic acid (PLA) fillers work alongside the body’s own collagen production to build gradual, durable volume. That volume is not biologically “locked in,” but it also does not depend on walling off a foreign material.
These materials have the most favorable complication profiles in the published literature, and they form the basis of Stoller Medical Group’s staged protocol. The trade-off is a less permanent mechanism in exchange for a dramatically lower long-term complication rate.
The PMMA Data Competitors Cite, and What They Leave Out
This is the core transparency section of the article. Below is the full data picture on PMMA, not a single cherry-picked study.
The Favorable 2016 Study Everyone Quotes
A retrospective evaluation published in The Journal of Sexual Medicine reviewed 729 patients treated across an estimated 1,500 PMMA microsphere sessions between 2007 and 2015. It reported:
- An average girth increase of 2.4 cm
- An overall satisfaction rate of 8.7 out of 10
A related figure appears elsewhere in the literature: after one to three sessions, average girth increased by 3.5 cm, or 134% (from 10.2 to 13.7 cm). The study’s authors suggested that nodules and irregularities, the only complication they noted, could be overcome with better injection technique and post-implantation care.
This is the data point nearly every competitor leads with, and often the only one they cite.
The 7-Year Follow-Up Study Almost No Provider Site Shows
The longer-term picture looks different. A 7-year follow-up study found that approximately 50% of patients developed lumps or irregularities, often requiring surgical correction. A separate review reported nodule formation in roughly 52% of cases in some PMMA series.
This matters because PMMA complications are difficult to reverse. Once nodules form, the usual treatment is surgical removal, followed by further procedures to minimize the resulting deformity.
Put the two findings side by side. An 8.7/10 satisfaction score from one early study sits alongside a roughly 50% long-term complication rate from longer follow-up. Both are real, and both deserve equal visibility before a man commits.
The FDA Approval Gap: Bellafill Was Never Cleared for This Use
- Correction of nasolabial folds (approved 2006)
- Moderate-to-severe atrophic cheek acne scars in adults 21 and older (added 2014)
Any use of Bellafill for penile girth is entirely off-label, and provider marketing pages rarely disclose this prominently. More broadly, every soft tissue filler the FDA has approved for cosmetic use since 2004, including polylactic acid, PMMA microspheres, hyaluronic acid, and autologous fat, is considered off-label when used for penile girth enhancement, whatever the brand name.
What the Medical Societies Actually Say, Named and Not Paraphrased
Most competitor content cites individual studies but avoids society-level guidance, because that guidance is unfavorable to permanent filler marketing. Here is what the three major bodies actually say.
SMSNA Position Statement
The Sexual Medicine Society of North America (SMSNA) position statement strongly recommends against permanent fillers such as paraffins and silicone. It is equally direct about psychological screening, stating that it is “not appropriate to perform augmentation procedures in men with uncontrolled psychological conditions, even if the patient is pushing to have them performed.”
The reasoning is clinical. Permanent materials cannot be reversed, and their complications can appear on an unpredictable timeline. That combination makes them a poor fit for an elective cosmetic procedure.
EAU Guidelines
The European Association of Urology (EAU) gives a strong recommendation against using silicone, paraffin, or petroleum jelly (Vaseline) for penile girth enhancement. It classifies many permanent subcutaneous approaches as experimental rather than established standard of care. The 2023 EAU guideline summary also gives significant weight to screening for dysmorphophobia (body dysmorphia focused on the penis).
AUA Update and the Convergence of Guidance
The AUA’s published update on penile girth enhancement addresses three issues: the FDA status of fillers, the risks of fat injection, and the limited scope of Penuma’s clearance. Taken together, the SMSNA (2024), EAU (2023), and AUA (2023/2024) agree on three points:
- Temporary HA/PLA fillers should remain first-line, with an acceptable safety profile.
- Permanent fillers are strongly discouraged outside IRB-monitored research.
- Psychological screening for body dysmorphia is a required part of responsible candidacy evaluation.
Three independent, authoritative medical bodies have reached the same cautious conclusion. That should carry more weight than a single satisfaction study.
Other “Permanent” Options Under the Microscope
PMMA is not the only material marketed as permanent. A safety-conscious man will encounter several others in his research.
Silicone Implants: FDA Clearance vs. Marketing Claims
Penuma’s actual clearance covers cosmetic correction of soft tissue deformities. It is not a blanket approval for elective enlargement in healthy men, although advertising often blurs that distinction. A retrospective analysis of the first 400 Penuma cases reported the following complications between 5 and 12 months:
- 4.8% seromas
- 4.5% hypertrophic scarring at the incision site
- 3.2% wound infections
- 1.25% superficial ulcerations
- 1% hematomas
The Nance v. International Medical Devices litigation alleged that marketing Penuma as “FDA-cleared” and safe failed to disclose the narrower scope of that clearance. Even the most legitimate device-based “permanent” option, then, carries a real surgical complication profile and legal controversy over how it is marketed.
Autologous Fat Transfer: The “Natural Permanent” Myth
Documented complications of penile fat transfer include pain, nodular hyperplasia or hypertrophy of fat, fat atrophy, contracture, scarring, and hematoma or wound complications. One case report describes a fatal fat embolism in a 30-year-old man after aesthetic penile fat injection for girth. The AUA’s conclusion is direct: injecting fat cells into the penis is not safe or reproducibly effective, despite its “all-natural” appeal.
Black-Market Silicone: The Danger Searchers Rarely See Named
Price-sensitive searchers looking for “permanent” results sometimes end up considering unlicensed injectors who offer raw or industrial silicone. This is a completely different risk category from clinic-administered fillers. FDA and Department of Justice documentation confirms that liquid silicone and other unapproved injectable substances have caused serious harm and death, and the FDA has never approved liquid silicone for augmentation.
The “Black Madam” case shows the worst-case outcome. A Philadelphia woman was charged with third-degree murder after a 20-year-old woman died days after receiving unlicensed silicone injections.
The published numbers likely understate the problem. Complications after penile girth injections are generally under-reported in the literature, so the true complication picture, especially for unlicensed procedures, is probably worse than published figures suggest.
Inflammatory complications from injectable fillers can also progress well beyond the injection site, from a local granuloma to a penile abscess or diffuse cellulitis spreading to the scrotum, perineum, or deep pelvic organs. No filler is risk-free. PLA has been linked to delayed granulomatous reactions, and one case report documents fulminant septic shock with multi-organ failure in a 31-year-old man after an HA penile filler.
Why Stoller Medical Group Does Not Use Off-Label Permanent Implant Materials
The evidence above leads directly to the practice’s clinical position. Stoller Medical Group has made a deliberate decision not to offer PMMA, silicone implants, or fat grafting for girth enhancement, in line with SMSNA and EAU guidance. The practice also does not perform surgical penile lengthening, because of its higher risk profile.
The Staged, Collagen-Stimulating Protocol
The practice uses Belefil®, a medical-grade, biocompatible, hyaluronic acid-based dermal filler placed beneath the penile skin. Treatment is staged across multiple sessions rather than delivered in a single dramatic procedure.
Staging serves three clinical purposes:
- Improved symmetry, because volume is built gradually and adjusted between sessions
- Reduced complication risk, because the practice avoids large single-volume implantation
- Smoother, more predictable outcomes that look natural in both flaccid and erect states
The procedure is outpatient and takes under one hour, with no cutting and no general anesthesia. Recovery takes roughly 10 days, compared with 40+ days reported for other permanent filler approaches, and sexual activity can typically resume within 7 to 10 days. Follow-up is usually scheduled 2 to 3 months after the first treatment.
The 80-90% Durable Improvement Standard
Stoller Medical Group reports 80-90% durable improvement in girth and volume, with gains of up to 1 to 1.5 inches. Results typically last 18 to 24 months, and optional touch-ups are available for maintenance.
Compared with PMMA, this means a somewhat shorter durability window in exchange for a very different complication profile from the roughly 50% nodule and irregularity rate in PMMA’s 7-year data. The practice’s experience of more than 15,000 procedures informs both the staged protocol and its conservative treatment planning, which focuses on proportion and balance.
Why This Approach Aligns With Psychological Screening Standards
Every patient goes through a comprehensive consultation with realistic goal-setting. This reflects the SMSNA’s emphasis on identifying uncontrolled psychological conditions before any procedure goes ahead. Patient education and informed consent are also thorough, so each patient understands he is choosing a durable, evidence-aligned option rather than an off-label permanent material.
How to Evaluate Any “Permanent” Girth Injection Claim Before Paying
The framework below can be applied to any provider, including this one.
Questions Every Safety-Conscious Patient Should Ask a Provider
- Is the filler material FDA-approved specifically for penile use, or is this an off-label application?
- What percentage of patients experience nodules, irregularities, or migration at 1 year, 3 years, and 7+ years after the procedure?
- If complications occur, what is the removal or correction process, and is it surgical?
- Does the consultation screen for unrealistic expectations or body dysmorphia, as SMSNA guidance recommends?
- What published, peer-reviewed data, not just internal testimonials, supports the stated satisfaction and durability rates?
Red Flags That Signal Marketing Over Medicine
- The provider cites one favorable study and never mentions longer-term follow-up data.
- A device or filler is described simply as “FDA-approved,” with no mention of its exact approved indication.
- Per-syringe pricing is unusually low, which can indicate unlicensed material sourcing or non-medical injectors.
- The provider’s educational materials never mention SMSNA, EAU, or AUA guidance.
- The provider promises a single-session “dramatic transformation” instead of a staged, conservative plan.
What Durable, Evidence-Aligned Treatment Costs
Stoller Medical Group publishes its pricing up front. Treatment is priced by the syringe. Cost starts at $7,500 and increases depending on each patient’s desired results. Most men start with a minimum of 10 syringes, and the average first procedure uses 15 syringes.
This per-syringe model follows the same conservative, incremental logic as the clinical protocol. Cost scales with a gradual, monitored approach rather than a single flat fee for a permanent implant. Optional touch-up sessions, used to maintain the 18 to 24 month result window, are priced separately.
Conclusion: Choosing Durability That Can Be Verified Over Permanence That Cannot Be Undone
“Permanent” is not a single clinical outcome. PMMA encapsulation, silicone implants, and fat grafts each carry distinct risks that are often under-reported and frequently glossed over in competitor marketing.
The PMMA data shows this clearly. One early study reported 8.7/10 satisfaction, while 7-year follow-up found nodule or irregularity rates of roughly 50%. Both findings are true, and both matter. The SMSNA, EAU, and AUA all urge caution against permanent fillers, and for an irreversible decision, that guidance should count for more than marketing copy.
Stoller Medical Group’s staged, collagen-stimulating protocol offers an evidence-aligned path to 80-90% durable improvement without taking on the risks of off-label permanent implants. For a safety-conscious professional, the better question is not “what lasts forever?” It is “what delivers the best verified outcome with the least irreversible risk?”
Schedule a Confidential Consultation With Stoller Medical Group
Men who value this level of clinical transparency can book a free, discreet consultation at any of five locations: Manhattan, Long Island, Albany, Chadds Ford (PA), and Eagan (MN).
Each consultation includes realistic goal-setting, a candidacy evaluation, and full disclosure of material options, expected outcomes, and pricing before any commitment is made. As a reminder, cost starts at $7,500, is priced by the syringe, and typically involves a minimum of 10 syringes.
For readers who have now seen the full risk-benefit picture and want an evidence-based, staged plan rather than an off-label permanent procedure, this is the logical next step. Dr. Roy B. Stoller brings more than 25 years of experience in aesthetic and restorative medicine, and the practice has performed more than 15,000 procedures.
